Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer.
Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer.
复制标题
在癌症中使用基于核磁共振的代谢组学检测耐药性。
DOI：
10.2217/bmm.09.15
复制
发表时间：
2009-06-01
影响因子：
2.2
通讯作者：
Serkova NJ
中科院分区：
文献类型：
--
作者：
Merz AL;Serkova NJ
癌细胞具有高度独特的代谢表型，其特征在于高葡萄糖摄取、增加的糖酵解活性、降低的线粒体活性、低生物能和增加的磷脂周转。这些代谢标志可以通过代谢技术（体外或体内）轻松评估，以监测对新型靶向药物的反应性和耐药性，其中发生细胞增殖的特异性抑制（细胞抑制作用），而不是直接诱导细胞死亡（细胞毒性）。使用现代分析技术结合统计方法，“代谢组学”，可以建立和验证反应者和无反应者的患者样本的总体代谢谱，提供额外的代谢终点。发现的代谢终点应转化为非侵入性代谢成像协议。
Cancer cells possess a highly unique metabolic phenotype, which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic and increased phospholipid turnover. These metabolic hallmarks can be readily assessed by metabolic technologies – either in vitro or in vivo – to monitor responsiveness and resistance to novel targeted drugs, where specific inhibition of cell proliferation (cytostatic effect) occurs rather than direct induction of cell death (cytotoxicity). Using modern analytical technologies in combination with statistical approaches, ‘metabolomics’, a global metabolic profile on patient samples can be established and validated for responders and nonresponders, providing additional metabolic end points. Discovered metabolic end points should be translated into noninvasive metabolic imaging protocols.